Analyst consensus rating
NovoCure Analyst Rating: Buy
Direct answer
NovoCure's consensus rating is Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $26.14.
Forecast evidence checked November 13, 2026.
Get free NovoCure email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.72
- Average price target
- $26.14
- High price target
- $52.00
- Low price target
- $15.00
- Low target gap
- +28%
- Target upside
- +123.1%
- High target gap
- +343.7%
- Target range width
- 315.7%
- Consensus rating
- Buy
- Analysts
- 7
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for NovoCure?
NovoCure has a verified Buy consensus. The same dataset has an average price target of $26.14.
How far are NovoCure's low and high targets from the recorded price?
The low target implies +28%, while the high target implies +343.7%.
How many analysts are included in NovoCure's consensus?
The verified consensus includes 7 analysts.
How is NovoCure's target upside or downside calculated?
The average target of $26.14 is divided by the recorded price of $11.72, then one is subtracted to produce +123.1%. This does not guarantee a future return.
When was NovoCure's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.